Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Galle, J.
Right arrow Articles by Seibold, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galle, J.
Right arrow Articles by Seibold, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 1452-1455
© 2003 European Renal Association-European Dialysis and Transplant Association

Invited Comment

Has the time come to use antioxidant therapy in uraemic patients?

Jan Galle and Stefan Seibold

Medizinische Klinik, Schwerpunkt Nephrologie, Universität Würzburg, Germany

Correspondence and offprint requests to: Professor J. Galle, Medizinische Klinik, Schwerpunkt Nephrologie, Universität Würzburg, Josef-Schneider-Strasse 2, D-97080 Würzburg, Germany. Email: j-c.galle@mail.uni-wuerzburg.de

Keywords: antioxidants; arteriosclerosis; cardiovascular disease; dialysis; oxidative stress; vitamin E

The first 150 words of the full text of this article appear below.

Introduction

Oxidative stress and inflammation currently resound throughout the scientific community as risk factors for arteriosclerosis and cardiovascular diseases. Already more or less reasonable recommendations appear in various lay-media, providing suggestions of how to prevent arteriosclerosis by antioxidative strategies, including, for example, daily consumption of red wine containing antioxidative tannins, or daily administration of vitamin E. What currently is the evidence for antioxidative treatment? Are there any validated recommendations particularly for uraemic patients bearing a high risk for arteriosclerosis and cardiovascular diseases? These questions will be addressed in the following.

Pathophysiological background

In the western world, cardiovascular diseases are the most common cause of death, not only for the general population but also for renal patients. Although development of cardiovascular diseases emerges from various factors, arteriosclerosis is accused of playing a crucial role in most of these patients. In recent years, arteriosclerosis has been recognized more and more as a chronic inflammatory process . . . [Full Text of this Article]

Oxidative stress and cardiovascular diseases in renal patients

Clinical investigations with antioxidative treatment and endothelial dysfunction as end point

Clinical investigations with antioxidative treatment and hard end points in the general population

Clinical investigations with antioxidative treatment and hard end points in dialysis patients

Open questions

Conclusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. X. Liu, F. F. Hou, Z. J. Guo, R. Nagai, W. R. Zhang, Z. Q. Liu, Z. M. Zhou, M. Zhou, D. Xie, G. B. Wang, et al.
Advanced Oxidation Protein Products Accelerate Atherosclerosis Through Promoting Oxidative Stress and Inflammation
Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 1156 - 1162.
[Abstract] [Full Text] [PDF]